Conjunctival hyperemia and the use of topical prostaglandins in glaucoma and ocular hypertension

Journal of Ocular Pharmacology and Therapeutics

Volumn 19, Issue 1, 2003, Pages 23-35

  Feldman, Robert M ^a,b  

^a UNIVERSITY OF TEXAS   (United States)

^b Herman Eye Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIMATOPROST; BRIMONIDINE; DORZOLAMIDE; LATANOPROST; PROSTAGLANDIN DERIVATIVE; TIMOLOL; TRAVOPROST; UNOPROSTONE ISOPROPYL ESTER;

CLINICAL TRIAL; CONJUNCTIVAL HYPEREMIA; DRUG RECEPTOR BINDING; DRUG USE; GLAUCOMA; HUMAN; INTRAOCULAR HYPERTENSION; INTRAOCULAR HYPOTENSION; INTRAOCULAR PRESSURE; PATIENT COMPLIANCE; REVIEW;

EID: 0037325109     PISSN: 10807683     EISSN: None     Source Type: Journal    
DOI: 10.1089/108076803762718088     Document Type: Review

References (73)

1. Boger, W.P., III. Shortterm "escape" and long-term "drift". The dissipation effects of the beta adrenergic blocking agents. Surv. Ophthalmol. 28:235-240, 1983.
2. Van Buskirk, E.M., and Fraunfelder, F.T. Ocular beta-blockers and systemic effects. Am. J. Ophthalmol. 98:623-624, 1994.
3. Stewart, W.C., and Castelli, W.P. Systemic side effects of topical beta-adrenergic blockers. Clin. Cardiol. 19:691-697, 1996.
4. Laibovitz, R.A., VanDenburgh, A.M., Felix, C., David, R., Batoosingh, A., Rosenthal, A., and Cheetham, J. Comparison of the ocular hypotensive lipid AGN 192024 with timolol. Dosing, efficacy, and safety evaluation of a novel compound for glaucoma management. Arch. Ophthalmol. 119:994-1000, 2001.
5. Hejkal, T.W., and Camras, C.B. Prostaglandin analogs in the treatment of glaucoma. Semin. Ophthalmol. 14:114-123, 1999.
6. Camras, C.B., and Alm, A. Initial clinical studies with prostaglandins and their analogues. Surv. Ophthalmol. 41(suppl.2):S61-S68, 1997.
7. 2a in the human eye. Graefes Arch. Clin. Exp. Ophthalmol. 222:139-141, 1985.
8. 2α. J. Biol. Chem. 272:27147-27154, 1997.
9. 2α receptors in the human trabecular meshwork. Invest. Ophthalmol. Vis. Sci. 39:315-321, 1998.
10. Kim, J.-W., Lindsey, J.D., Wang, N., and Weinreb, R.N. Increased human scleral permeability with prostaglandin exposure. Invest. Ophthalmol. Vis. Sci. 42:1514-1521, 2001.
11. 2α, and latanoprost acid on isolated ocular blood vessels in vitro. J. Ocul. Pharmacol. Ther. 14:119-128, 1998.
12. 2α-induced ocular hyperemia. Exp. Eye Res. 59:401-408, 1994.
13. 2α-induced ocular surface hyperemia by sensory nerves in rabbits. Curr. Eye Res. 16:886-890, 1997.
14. Stjernschantz, J. Prostaglandins as ocular hypotensive agents; development of an analogue for glaucoma treatment. In Advances in Prostaglandin, Thromboxane, and Leukotriene Research, B. Samuelsson et al., eds., Raven Press, Ltd., New York, 1995, pp. 63-68.
15. 2α-isopropylester eye drops: effects in normal human eyes. Br. J. Ophthalmol. 73:419-426, 1989.
16. Villumsen, J., and Alm, A. Ocular effects of two different prostaglandin F2 alpha esters. A double-masked cross-over study on normotensive eyes. Acta Ophthalmol. 68:341-343, 1990.
17. Camras, C.B., Schumer, R.A., Marsk, A., Lustgarten, J.S., Serle, J.B., Stjernschantz, J., Bito, L.Z., and Podos, S.M. Intraocular pressure reduction with PhXA34, a new prostaglandin analogue, in patients with ocular hypertension. Arch. Ophthalmol. 110:1733-1738, 1992.
18. 2α analogue. Effect on intraocular pressure in patients with ocular hypertension. Br. J. Ophthalmol. 76:214-217, 1992.
19. 2α analogue (PhXA41). An in-hospital, placebo-controlled study. Arch. Ophthalmol. 111:657-661, 1993.
20. Nagasubramanian, S., Sheth, G.P., Hitchings, R.A., and Stjernschantz, J. Intraocular pressure-reducing effect of PhXA41 in ocular hypertension. Comparison of dose regimens. Ophthalmology 100:1305-1311, 1993.
21. Alm, A., Villumsen, J., Törnquist, P., Mandahl, A., Airaksinen, J., Tuulonen, A., Marsk, A., Resul, B., and Stjernschantz, J. Intraocular pressure-reducing effect of PhXA41 in patients with increased eye pressure. A one-month study. Ophthalmology 100:1312-1317, 1993.
22. Brandt, J.D., VanDenburgh, A.M., Chen, K., and Whitcup, S.M., for the Bimatoprost Study Group 1. Comparison of once- or twice-daily bimatoprost with twice-daily timolol in patients with elevated IOP. A 3-month clinical trial. Ophthalmology 108:1023-1032, 2001.
23. Woodward, D.F., Krauss, A.H.-P., Chen, J., Lai, R.K., Spada, C.S., Burk, R.M., Andrews, S.W., Shi, L., Liang, Y., Kedzie, K.M., Chen, R., Gil, D.W., Kharlamb, A., Archeampong A., Ling, J., Madhu, C., Ni, J., Rix, P., Usansky, J., Usansky, H., Weber, A., Welty, D., Yang, W., Tang-Liu, D.D.-S., Garst, M.E., Brar, B., Wheeler, L.A., and Kaplan, L.J. The pharmacology of bimatoprost (Lumigan™). Surv. Ophthalmol. 45(suppl.4):S337-S345, 2001.
24. Sherwood, M., and Brandt, J., for the Bimatoprost Study Groups 1 and 2. Six-month comparison of bimatoprost once-daily and twice-daily with timolol twice-daily in patients with elevated intraocular pressure. Surv. Ophthalmol. 45(suppl.4):S361-S368, 2001.
25. Tsukamoto, H., Yokoyama, T., Okada, K., Okada, M., Mochizuki, H. and Mishima, H.K. Substituting latanoprost (Xalatan™) for isopropyl unoprostone (Rescula™) in monotherapy and combination therapy [letter]. Acta Ophthalmol. Scand. 78:604-605, 2000.
26. 2α metabolite, 0.12% unoprostone, in subjects with chronic open-angle glaucoma or ocular hypertension. Curr. Med. Res. Opin. 15:87-93, 1999.
27. Lumigan™ [package insert]. Irvine, CA: Allergan, Inc; 2001.
28. Rescula® [package insert]. Duluth, GA: CIBA Vision; 2000.
29. Travatan™ [package insert]. Fort Worth, TX: Alcon Pharmaceuticals; 2001.
30. Pharmaceutical Approvals Monthly on the Web. Lumigan, travatan statistically, not clinically superior to timolol, FDA says. September 2001. Available at: http://www.pharmaceuticalapprovals.com. Accessed July 10, 2002.
31. Netland, P.A., Landry, T., Sullivan, E.K., Andrew, R., Silver, L., Weiner, A., Mallick, S., Dickerson, J., Bergamini, M.V.W., Robertson, S.M., Davis, A.A., and the Travoprost Study Group. Travoprost compared with latanoprost and timolol in patients with open-angle glaucoma or ocular hypertension. Am. J. Ophthalmol. 132:472-484, 2001.
32. Xalatan® [package insert]. Kalamazoo, MI: Pharmacia & Upjohn; 2000.
33. Mishima, H.K., Masuda, K., Kitazawa, Y., Azuma, I., and Araie, M. A comparison of latanoprost and timolol in primary open-angle glaucoma and ocular hypertension. A 12-week study. Arch. Ophthalmol. 114:929-932, 1996.
34. Alm, A., Stjernschantz, J., and the Scandinavian Latanoprost Study Group. Effects on intraocular pressure and side effects of 0.005% latanoprost applied once daily, evening or morning. A comparison with timolol. Ophthalmology 102:1743-1752, 1995.
35. Camras, C.B., and the United States Latanoprost Study Group. Comparison of latanoprost and timolol in patients with ocular hypertension and glaucoma. A six-month, masked, multicenter trial in the United States. Ophthalmology 103:138-147, 1996.
36. Watson, P., Stjernschantz, J., and the Latanoprost Study Group. A six-month, randomized, double-masked study comparing latanoprost with timolol in open-angle glaucoma and ocular hypertension. Ophthalmology 103:126-137, 1996.
37. Camras, C.B., Wax, M.B., Ritch, R., Weinreb, R., Robin, A.L., Higginbotham, E.J., Lustgarten, J., Stewart, W.C., Sherwood, M., Krupin, T., Wilensky, J., Cioffi, G.A., Katz, L.J., Schumer, R.A., Kaufman, P.L., Minckler, D., Zimmerman, T., Stjernschantz, J., and the United States Latanoprost Study Group. Latanoprost treatment for glaucoma: effects of treating for 1 year and of switching from timolol. Am. J. Ophthalmol. 126:390-399, 1998.
38. Aung, T., Wong, H.T., Yip, C.C., Leong, J.Y.H., Chan, Y.-H., and Chew, P.T.K. Comparison of the intraocular pressure-lowering effect of latanoprost and timolol in patients with chronic angle closure glaucoma. A preliminary study. Ophthalmology 107:1178-1183, 2000.
39. Stewart, W.C., Stewart, J.A., and Kapik, B.M. The effects of unoprostone isopropyl 0.12% and timolol maleate 0.5% on diurnal intraocular pressure. J. Glaucoma 7:388-394, 1998.
40. FDA/CDER resources page. New and Generic Drug Approvals: 1998-2002. Comparison of the effects of different concentrations of unoprostone isopropylate ophthalmic solution on intraocular pressure in subjects with primary open angle glaucoma or ocular hypertension. Available at: http://www.fda.gov/cder/approval. Accessed March 29, 2002.
41. Goldberg, I., Cunha-Vaz, J., Jakobsen, J.-E., Nordmann, J.-P., Trost, E., Sullivan, E.K., and the International Travoprost Study Group. Comparison of topical travoprost eye drops given once daily and timolol 0.5% given twice daily in patients with open-angle glaucoma or ocular hypertension. J. Glaucoma 10:414-422, 2001.
42. Fellman, R.L., Sullivan, E.K., Ratliff, M., Silver, L.H., Whitson, J.T., Turner, F.D., Weiner, A.L., Davis, A.A. and the Travoprost Study Group. Comparison of travoprost 0.0015% and 0.004% with timolol 0.5% in patients with elevated intraocular pressure. A 6-month, masked, multicenter trial. Ophthalmology 109:998-1008, 2002.
43. Camras, C.B. Travoprost compared with latanoprost and timolol in patients with open-angle glaucoma or ocular hypertension [letter]. Am. J. Ophthalmol. 133:732-733, 2002.
44. Gandolfi, S., Simmons, S.T., Sturm, R., Chen, K., and Van Denburgh, A.M., for the Bimatoprost Study Group 3. Three-month comparison of bimatoprost and latanoprost in patients with glaucoma and ocular hypertension. Adv. Ther. 18:110-121, 2001.
45. DuBiner, H., Cooke, D., Dirks, M., Stewart, W.C., VanDenburgh, A.M., and Felix, C. Efficacy and safety of bimatoprost in patients with elevated intraocular pressure: a 30-day comparison with latanoprost. Surv. Ophthalmol. 45(suppl 4):S353-S360, 2001.
46. Kobayashi, H., Kobayashi, K., and Okinami, S. A comparison of intraocular pressure-lowering effect of prostaglandin F2-α analogues, latanoprost, and unoprostone isopropyl. J. Glaucoma 10:487-492, 2001.
47. Aung, T., Chew, P.T.K., Yip, C.-C., Chan, Y.-H., See, J.L.S., Khng, C.G., Hoh, S.-T., Ng, L.-H., and Lee, H.-M. A randomized double-masked crossover study comparing latanoprost 0.005% with unoprostone 0.12% in patients with primary open-angle glaucoma and ocular hypertension. Am. J. Ophthalmol. 131:636-642, 2001.
48. Susanna, R., Giampani, J., Jr., Borges, A.S., Jr., Vessani, R.M., and Jordao, M.L.S. A double-masked, randomized clinical trial comparing latanoprost with unoprostone in patients with open-angle glaucoma or ocular hypertension. Ophthalmology 108:259-263, 2001.
49. Stewart, W.C., Day, D.G., Stewart, J.A., Schuhr, J., and Latham, K.E. The efficacy and safety of latanoprost 0.005% once daily versus brimonidine 0.2% twice daily in open-angle glaucoma or ocular hypertension. Am. J. Ophthalmol. 131:631-635, 2001.
50. Stewart, W.C., Day, D.G., Stewart, J.A., Holmes, K.T., Leech, J.N., Rowan, C.T., and Schwartz, G.F. Therapeutic success of latanoprost 0.005% compared to brimonidine 0.2% in patients with open-angle glaucoma or ocular hypertension. J. Ocul. Pharmacol. Ther. 16:557-564, 2000.
51. Kampik, A., Arias-Puente, A., O'Brart, D.P.S. Vuori, M.-L., and the European Latanoprost Study Group. Intraocular pressure-lowering effects of latanoprost and brimonidine therapy in patients with open-angle glaucoma or ocular hypertension: a randomized observer-masked multicenter study. J. Glaucoma 11:90-96, 2002.
52. DuBiner, H.B., Mroz, M., Shapiro, A.M., and Dirks, M.S., for the Brimonidine vs. Latanoprost Study Group. A comparison of the efficacy and tolerability of brimonidine and latanoprost in adults with open-angle glaucoma or ocular hypertension: a three-month, multicenter, randomized, double-masked, parallel-group trial. Clin. Ther. 23:1969-1983, 2001.
53. O'Donoghue, E.P., and the UK and Ireland Latanoprost Study Group. A comparison of latanoprost and dorzolamide in patients with glaucoma and ocular hypertension: a 3 month, randomised study. Br. J. Ophthalmol. 84:579-582, 2000.
54. Polo, V., Larrosa, J.M., Gomez, M.L., Pablo, L., and Honrubia, F.M. Latanoprost versus combined therapy with timolol plus dorzolamide: IOP-lowering effect in open-angle glaucoma. Acta Ophthalmol. Scand. 79:6-9, 2001.
55. Broadway, D.C., Grierson, I., O'Brien, C., and Hitchings, R.A. Adverse effects of topical antiglaucoma medication. II. The outcome of filtration surgery. Arch. Ophthalmol. 112:1446-1454, 1994.
56. Gwynn, D.R., Stewart, W.C., Pitts, R.A., McMillan, T.A., and Hennis, H.L. Conjunctival structure and cell counts and the results of filtering surgery. Am. J. Ophthalmol. 116:464-468, 1993.
57. Arici, M.K., Demircan, S., Topalkara, A., Gler, C., Aker, H., and Arici, D.S. Effect of conjunctival structure and inflammatory cell counts on intraocular pressure after trabeculectomy. Ophthalmologica 213:371-375, 1999.
58. Aritürk, N., Öge, I., Baris, S., Erkan, D., Süllü, Y., and Koc, F. The effects of antiglaucomatous agents on conjunctiva used for various durations. Int. Ophthalmol. 20:57-62, 1996-97.
59. Heuer, D.K., Parrish, R.K., 2nd, Gressel, M.G., Hodapp, E., Palmberg, P.F., and Anderson, D.R. 5-fluorouracil and glaucoma filtering surgery. II. A pilot study. Ophthalmology 91:384-394, 1984.
60. Weinreb, R.N. Adjusting the dose of 5-fluorouracil after filtration surgery to minimize side effects. Ophthalmology 94:564-570, 1987.
61. Ticho, U., and Ophir, A. Regulating the dose of 5-fluorouracil to prevent filtering bleb scarring. Ann. Ophthalmol. 23:225-229, 1991.
62. Broadway, D.C., Grierson, I., O'Brien, C., and Hitchings R.A. Adverse effects of topical antiglaucoma medication. I. The conjunctival cell profile. Arch. Ophthalmol. 112:1437-1445, 1994.
63. Baudouin, C. Side effects of antiglaucomatous drugs on the ocular surface. Curr. Opin. Ophthalmol. 7:80-86, 1996.
64. Baudouin, C., Pisella, P.-J., Fillacier, K., Goldschild, M., Becquet, F., De Saint Jean, M., and Béchetoille, A. Ocular surface inflammatory changes induced by topical antiglaucoma drugs. Human and animal studies. Ophthalmology 106:556-563, 1999.
65. Pisella, P.-J., Fillacier, K., Elena, P.P., Debbasch, C., and Baudouin, C. Comparison of the effects of preserved and unpreserved formulations of timolol on the ocular surface of albino rabbits. Ophthalmic Res. 32:3-8, 2000.
66. Bendel, E., and Juzych, M.S. Principles and complications of medical therapy of glaucoma. In Clinical Pathways in Glaucoma, Zimmerman, T.J., and Kooner, K.S., eds., Thieme, New York, 2001, pp. 427-455.
67. Broadway, D.C., Grierson, I., Sturmer, J., and Hitchings, R.A. Reversal of topical antiglaucoma medication effects on the conjunctiva. Arch. Ophthalmol. 114:262-267, 1996.
68. Collaborative Normal-Tension Glaucoma Study Group. The effectiveness of intraocular pressure reduction in the treatment of normal-tension glaucoma. Am. J. Ophthalmol. 126:498-505, 1998.
69. The Advanced Glaucoma Intervention Study Investigators. The Advanced Glaucoma Intervention Study (AGIS): 7. The relationship between control of intraocular pressure and visual field deterioration. Am. J. Ophthalmol. 130:429-440, 2000.
70. Stewart, W.C., Kolker, A.E., Sharpe, E.D., Day, D.G., Holmes, K.T., Leech, J.N., Johnson, M., and Cantrell, J.B. Factors associated with long-term progression or stability in primary open-angle glaucoma. Am. J. Ophthalmol. 130:274-279, 2000.
71. Weinreb, R.N. Compliance with medical treatment of glaucoma. J Glaucoma 1:134-136, 1992.
72. Boccuzzi, S.J., Wogen, J., Fox, J., Sung, J.C.Y., Shah, A.B., and Kim, J. Utilization of oral hypoglycemic agents in a drug-insured U.S. population. Diabetes Care 24:1411-1415, 2001.
73. Enström, I., Pennert, K., and Lindholm, L.H. Durability of improvement achieved in a clinical trial. Is compliance an issue? J. Fam. Pract. 49:634-637, 2000.